| Aug 1 |
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
|
| Aug 1 |
Sage Therapeutics, Inc., (SAGE) Q2 2024 Earnings Call Transcript
|
| Jul 31 |
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
|
| Jul 31 |
Sage Therapeutics GAAP EPS of -$1.70 misses by $0.05, revenue of $8.65M misses by $0.35M
|
| Jul 31 |
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
|
| Jul 30 |
Sage Therapeutics Q2 2024 Earnings Preview
|
| Jul 30 |
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
|
| Jul 30 |
Sage adds another downgrade as TD Cowen cuts after mid-stage setback
|
| Jul 26 |
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
| Jul 25 |
Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
|
